Please login to the form below

Not currently logged in
Email:
Password:

aflibercept

This page shows the latest aflibercept news and features for those working in and with pharma, biotech and healthcare.

NHS wins legal fight with pharma over off-label Avastin

NHS wins legal fight with pharma over off-label Avastin

Bayer's Eylea (aflibercept) and Novartis' Lucentis (ranibizumab) are among the top selling drugs in England, number 2 and number 5 in the top ten medicines by spending in the

Latest news

  • After Lucentis setback, Novartis trumpets data on follow-up drug After Lucentis setback, Novartis trumpets data on follow-up drug

    The experimental therapy – called brolucizumab (RTH258) – showed its was superior to a Bayer and Regeneron’s Eylea (aflibercept) in tackling a key disease activity marker in age-related macular degeneration (AMD),

  • Allergan’s abicipar matches AMD blockbuster Lucentis in phase III Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

    Both studies will continue for another year. Lucentis – sold by Roche in the US and Novartis in Europe and other markets – and Regeneron’s Eylea (aflibercept) currently dominate the wet AMD

  • Regeneron’s Dupixent and Praluent fall short Regeneron’s Dupixent and Praluent fall short

    Regeneron needs the two drugs, both partnered with Sanofi, to ramp up sales quickly before its ophthalmic blockbuster Eylea (aflibercept) - which generates nearly two-thirds of its revenues - starts to lose

  • Regeneron and Bayer drop AMD combination Regeneron and Bayer drop AMD combination

    Eylea (aflibercept) – which is partnered with Bayer – is the market leader in AMD with sales of $2.73bn in the first nine months of the year, but is facing the threat ... The studies assessed two different doses of nesvacumab in combination with

  • EMA clears Bayer's Stivarga for liver cancer EMA clears Bayer's Stivarga for liver cancer

    Stivarga is a key component among a new generation of pharma products - along with cancer drug Xofigo (radium-223 dichloride), anticoagulant Xarelto (rivaroxaban), ophthalmic therapy Eylea (aflibercept) and pulmonary arterial hypertension

More from news
Approximately 20 fully matching, plus 70 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    330. Ocular Therapeutics (US). Regeneron (US). Licence collaboration. Hydrogel sustained release aflibercept (Eylea) for wet macular degeneration.

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration &licence. $134. Regeneron/ Bayer. Ophthalmology combination therapy: nesvacumab (Ang2 antibody) and aflibercept (VEGF trap).

  • Interview: Beate Wieseler, IQWIG Interview: Beate Wieseler, IQWIG

    In addition fellow German firm Bayer criticised IQWiG's assessment of trial designs after the HTA body deemed data for eye drug Eylea (aflibercept) unsuitable in order to judge its

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics